Denver Health And Hospital Authority

Denver Health And Hospital Authority, doing business as Denver Health, is a 555-bed academic healthcare system and U.S. government entity based in Denver, Colorado, that operates as both a prime contractor and prime recipient on federal contracts and grants spanning post-marketing drug surveillance, vaccine safety research, health services research, and clinical training and education programs. Denver Health competes in full-and-open procurements with no set-aside designations across its federal portfolio. The organization functions predominantly as a subrecipient and subcontractor (59% of recent awards), with 41% prime awards. Since 2001, Denver Health has built a substantial federal contracting and grant footprint anchored by two major vehicle seats: a $149 million CDC Vaccine Safety Datalink multiple-award IDIQ and an $8.5 million FDA non-medical use surveillance IDIQ awarded in September 2026.

Denver Health's capability portfolio centers on epidemiological surveillance, data analytics, and clinical research infrastructure. Representative prime contract work includes a $309,340 FDA delivery order for the National Survey Investigating Hallucinogenic Trends (NSIHT) data collection on selected drugs of interest, a $249,999.99 substance-abuse survey purchase order on psychedelic use motivations and contextual factors, and a $1,353,024 FDA definitive contract for bias evaluation and recruitment-retention optimization in online research settings. The organization holds a $3,015,216.50 CDC delivery order under the Vaccine Safety Datalink contract for ongoing vaccine safety monitoring. On the guard-services side, Denver Health received a $495,000 sole-source purchase order from Immigration and Customs Enforcement for unarmed guard services at its Correctional Care Medical Facility through July 31, 2028.

Customer concentration is heavily tilted toward Department of Health and Human Services operating divisions. CDC Pittsburgh commands the largest share by potential value (18 awards, $217.6 million combined potential value), followed distantly by FDA (20 awards, $35 million combined potential value) and AHRQ (12 awards, $5.9 million combined potential value). The top five HHS components account for 99% of combined potential value across all awards. Activity has grown substantially—15 awards in 2022 to 128 in 2024, with recent moderation to 104 in 2025 and 23 in 2026 (through September)—but 20 awards carrying $6 million in combined potential value face ultimate completion inside the next twenty-four months, creating recompete exposure.

Denver Health's prime-contract vehicles concentrate on CDC and FDA IDIQs. Beyond the two major seats named above, the vendor places work under five additional parent vehicles: Indefinite Delivery Contract HHSA290200600020I (11 task orders, $5.9 million), HHSD200200100088I (9 task orders, $14.8 million), FDA Prescription Drug Abuse Summary Reports (8 task orders, $1.8 million), and several others. The organization subcontracts primarily to academic institutions including the University of Pittsburgh (on clinical trial work such as the CAVALIER hemorrhagic shock study), the University of Colorado, and Northwestern University on research projects spanning infectious disease, substance use outcomes, and maternal health.

On the federal grant side, Denver Health is a prolific recipient across HRSA, NIDA, NHLBI, NSF, and other NIH institutes. Recent prime grant awards include a $634,042 NIDA project grant for NSIHT surveillance (CFDA 93.279) studying psychedelic use patterns nationwide through December 2030, a $346,474 HRSA Primary Care Training and Enhancement grant (CFDA 93.884) for street medicine curriculum development in the Denver Community Health Family Medicine Residency through June 2031, a $540,771 NHLBI project grant (CFDA 93.837) for personalized stroke risk stratification in atrial fibrillation using machine learning and social determinants of health data, and a $186,728 HRSA Health Services Research Training grant for emergency department linkage-to-care interventions for people experiencing homelessness. Denver Health serves as a subrecipient on numerous additional grants flowing through the Colorado Department of Public Health and Environment, the University of Colorado, and state health and child-welfare agencies, with sub-awards supporting HIV surveillance, STD prevention, WIC administration, family planning, and child maltreatment prevention.

SCI-reported federal service-contract invoicing totaled $5.5 million across FY2022–FY2024, with $1.2 million in FY2022 and $4.3 million in FY2024 (FY2023 reported zero invoicing). Reported FTE delivery ranged from 10.7 FTEs in FY2022 to 14.0 in FY2024. On SCI-reportable prime contracts, government-paid hourly rates ran from a 10th percentile of $32.84/hr through a median of $111.75/hr to a 90th percentile of $206.16/hr, reflecting a workforce mix spanning administrative and clinical labor. Across SCI-reportable prime contracts, sub-hours share averaged 0%, indicating Denver Health performs most work with its own staff; the organization named one subcontractor across its SCI-reportable prime base. The organization's award concentration by NAICS and PSC code spreads across research and development in life sciences, administrative and professional consulting, health services analysis, and security guard services, reflecting both its clinical-research core and its role as Denver's safety-net academic health system serving low-income and minority populations.